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S U M M A R Y
During a two-decade battle against polio, the Chinese government has saved more than one million
children from physical disability caused bywild poliovirus infection. Today, the Chinese government still
faces an arduous task in (1) preventing the entry and transmission of wild poliovirus from surrounding
polio-endemic countries, (2) ﬁnding and stopping the outbreak of polio caused by the recycling of
vaccine-derived poliovirus, (3) reducing vaccine-associated paralytic poliomyelitis (VAPP) cases, and (4)
improving the State compensation system. The scientiﬁcmonitoring system established in China and the
immunity strategy implemented not only allow children in China to avoid lifelong disability or
premature death due to polio infection, but also provide success stories for the World Health
Organization that can be used for the speciﬁcation of quality control indices for monitoring polio,
classiﬁcation and diagnosis criteria for acute ﬂaccid paralysis cases, and identiﬁcation and emergency
treatment principles for imported wild poliovirus.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The World Health Organization (WHO) released the ‘‘Global
polio eradication initiative, strategic plan 2004–2008’’ in 2004 and
planned to intercept the transmission of wild poliovirus (WPV) by
2004/2005, certify the global eradication of polio by 2006/2008,
and stop the use of the poliomyelitis live oral vaccine by 2009.1
However, the schedule has been subject to delay. As reported by
the WHO, four countries still need to curb the local spread of
poliovirus, i.e., the endemic countries of Afghanistan, India,
Nigeria, and Pakistan.2 The global eradication of polio will be a
long journey.
The Ministry of Health of the People’s Republic of China,
along with several government departments, released the
‘‘Instruction advice on veriﬁcation of cases related to polio
vaccines and handling of remaining problems’’ on July 17,
2008 (Wei Ban Fa [2008] No. 40). The four-year incident wherein
the oral polio vaccines caused disabilities among Chinese
children has ended for the time being, but is far from being
completely resolved. During a two-decade battle against polio,
the Chinese government has saved more than one million
children from physical disability brought about by infection
with the wild poliovirus.1–4 The scientiﬁc monitoring system
established and the immunity strategy implemented in China* Corresponding author. Tel.: +86 10 66939770; fax: +86 10 66939770.
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doi:10.1016/j.ijid.2010.02.2252are included in the ﬁrst law on the prevention and treatment of
epidemic diseases promulgated in 1989 – ‘‘The People’s Republic
of China Epidemic Disease Prevention and Treatment Law’’.
The law requires governments at all levels to organize and
lead vaccination based on the immunization program and
guarantees the funds related to this for training, technical
guidance, monitoring, appraisal, epidemiological survey, and
emergency treatment within the administrative regions. Only
the Ministry of Health and the health agencies of the provincial
(autonomous region, municipality directly under the direction
of Central government) government can specify the immuniza-
tion program, while its health institutions organize implemen-
tation.5
The strategy not only allows children in China to avoid lifelong
disability or premature death due to polio infection, but also
provides theWHOwith successful experiences that can be used for
the speciﬁcation of quality control indices for monitoring polio,
classiﬁcation and diagnosis criteria for acute ﬂaccid paralysis (AFP)
cases, and identiﬁcation and emergency treatment principles for
imported wild poliovirus.
2. History of polio control in China
China reported 20 000 to 43 000 polio cases each year in the
early 1960s, making it a major affected area. At this time, China
successfully developed an attenuated live polio vaccine through its
own efforts, and the number of polio cases and deaths dropped
sharply along the course of its promotion.ses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. World Health Organization vaccine-preventable diseases: monitoring
system 2008 global summary (Polio); last updated December 16, 2008. Polio refers
to all polio cases (indigenous or imported), including polio cases caused by vaccine-
derived polio viruses (VDPV); it does not include cases of vaccine-associated
paralytic polio (VAPP) and cases of non-polio acute ﬂaccid paralysis (AFP).
L.-P. Zou et al. / International Journal of Infectious Diseases 14S (2010) e9–e1310In 1978, China started to implement the planned immunization
schedule, further reducing the incidence rate. Figure 1 presents the
number of polio cases each year from 1989 to 2006. The data come
from the ‘‘WHO vaccine-preventable diseases: monitoring system
2008 global summary’’.3
At the 41st World Health Conference in 1988 , a target date of
2000 was proposed for the global eradication of polio. However,
The West Paciﬁc Area, to which China belongs, aimed to eradicate
polio by 1995. To meet this target, the Chinese government
established the national AFP monitoring system and polio
laboratory network in 1991, adopted a uniform deﬁnition for
AFP cases, and developed the active monitoring and ‘zero’ case
reporting of such cases. Dead zones, highly dangerous areas, and
weakly monitored areas were identiﬁed by analysis through
computer network management and geographical information
systems.
3. The campaign to eradicate polio
The ﬁrst round vaccination campaign to eradicate polio and
boost the immunity of children aged less than 4 years was
launched nationwide on December 5, 1993.4 Party and State
leaders and friends from international organizations in China
attended this campaign. International organizations supported the
Chinese government’s commitment to theworld to eradicate polio.
Launching the national campaign to boost immunity in this
populous state was a critical and decisive measure required for
China to eradicate polio as scheduled.3 The presence of State
[(Figure_2)TD$FIG]Figure 2. In China, on December 5, 1993, General Secretary Jiang Zemin fed polioleaders at each activity of the Immunity Boost Campaign aided its
promotion (Figure 2).
The Chinese government carried out enhanced immunization2
(Table 1). Firstly there was a strengthening of the national
immunization program. Secondly immunization surveillance was
implementedwith the following results: the incidence rate of non-
polio AFP cases among children aged <15 years was maintained
above 1/100 000. A review of the quality of the AFP surveillance
system in China for 1998–2007 is shown in Table 2. For example,
3001 AFP cases were reported in 2007. Based on the virological
classiﬁcation standard, 3000 cases were discarded as non-polio
cases and one case was classiﬁed as polio compatible. No
indigenous or imported WPV was found in China in 2007. The
AFP system ranwell in 2007, and all the surveillance indicatorsmet
the requirements of the Ministry of Health in China and the WHO
(Table 2).6,7
China has established a poliomyelitis laboratory network,
which has been incorporated into the WHO’s Global Poliomyelitis
Laboratory Network. Whether or not AFP is caused by WPV must
be determined by etiological diagnosis in laboratories. Poliomy-
elitis was the ﬁrst disease among viral infections that took
etiological diagnosis as its monitoring basis. China built its
poliomyelitis laboratory network in 1992, comprising the National
Poliomyelitis Laboratory and provincial laboratories established in
the provinces. Provincial laboratories are responsible for virus
isolation and identiﬁcation. The National Poliomyelitis Laboratory
is responsible for reviewing and identifying whether the virus is a
WPV through molecular virological methods. Provincial laborato-
ries in China implement quality control as per WHO requirements
for national poliomyelitis laboratories, including the following:
laboratories should report the results of at least 80% of all AFP feces
samples within 30 days of receipt; the laboratory must complete
virus isolation of 150 feces samples each year; the laboratory
should have a 10% or higher correct identiﬁcation rate for non-
polio enterovirus and 80% or higher rate for isolated poliomyelitis
virus; the pass rate of professional skill reviews must be 80% and
the pass rate of laboratory skill tests must be 80%. After having
received the isolated virus from provincial laboratories, the
National Poliomyelitis Laboratory completes the type identiﬁca-
tionwithin 30 days. The entire laboratory network adopts the same
records, forms, and sensitive cells from the same source in
conformity with international rules for virus isolation. The same
blood serum for virus identiﬁcation is also used to guarantee the
quality of etiological monitoring.
The poliomyelitis laboratory network in China tests about 10
000 samples each year. The annual testing volume of isolated polio
virus and wild strains detected by restriction fragment length
polymorphism–polymerase chain reaction (RFLP–PCR) accounts
for 85% of the total work volume in the WHOWest Paciﬁc Region.vaccine pills to a young girl, ofﬁcially launching National Immunization Day.
Table 1
Report of oral poliomyelitis vaccine (OPV) immunization coverage in China, 1993–2004a
Year First round of OPV immunization Second round of OPV immunization
Number of
vaccinations
Actual number of
vaccinations
Vaccine
coverage %
Number of
vaccinations
Actual number
of vaccinations
Vaccine
coverage %
93/94 75 414 906 73 948 557 98.1 81 684 792 74 471 268 91.2
94/95 69 356 581 68 053 713 98.1 71 639 272 69 248 835 96.7
95/96 64 102 729 62 551 298 97.6 64 558 007 64 326 907 99.6
96/97 56 345 426 55 444 380 98.4 57 270 562 56 454 610 98.6
97/98 54 409 723 53 240 021 97.9 55 039 311 53 991 489 98.1
98/99 46 436 344 45 683 792 98.4 47 387 681 46 668 264 98.5
99/00 41 185 159 40 418 525 98.1 41 378 508 40 684 500 98.3
00/01 29 309 256 25 799 922 98.1 26 251 684 25 762 149 98.1
01/02 31 931 970 31 313 185 98.1 37 175 857 36 507 459 98.2
02/03 36 376 297 35 702 617 98.1 37 119 774 36 419 104 98.1
03/04 33 583 074 32 665 421 97.3 34 048 673 33 097 375 97.2
a See reference 2.
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sequencing the virogene of epidemic WPV strains collected up
until 1989 and built a gene bank of Chinese local WPV sequences
through sequential analysis. The laboratory also conducted
molecular epidemiological work on WPV and proved that the last
case of indigenous WPV in China occurred in September 1994.8 In
1995–1996, overseas cases of WPV were found in Yunnan
Province. A few years later, in 1999, WPV was isolated in Qinghai
Province. In a timely manner, the laboratory correctly identiﬁed
the WPV isolated in Yunnan as being the same as the earlier
imported cases. This was done by comparing the newly isolated
WPV with the local epidemic WPV found in the past; results were
reviewed and conﬁrmed by the international laboratory. This also
provided important, scientiﬁc, and reliable evidence for the WHO
(West Paciﬁc) Polio Eradication Committee to endorse China as a
polio-free area. Following this, vaccine recombinant virus was
reported for the ﬁrst time; recombinant strains of different types of
virus. This virus has greater virulence and shows local circulation
in Mainland China, which has led to heightened international
concern.9
As estimated by the WHO, the minimum demand for polio
vaccine in China in 1993 was 410 million units per year or 510
million units if an ideal plan was adopted. The maximum capacity
in China at that timewas 325million units. The serious inadequacy
of vaccine supplies affected the Immunity Boost Campaign for the
eradication of polio in China. Therefore, the Japanese government
and the Japan International Cooperation Agency (JICA) donated
more than US$ 2.7 million, while the Rotary International, Rotary
Club in Japan and UNICEF donated more than US$ 2.7 million for
the purchase of polio vaccines in 1993, totaling 120 million units.Table 2
Classiﬁcation of AFP reported cases in China, 1998–2007a
Year AFP reported
incidence rate/100 000
AFP reported cases AFP
Wi
2007 1.37 3001 0
2006 2.02 5635 0
2005 1.94 5425 0
2004 1.86 5285 0
2003 1.79 5107 0
2002 1.89 5415 0
2001 1.88 5395 0
2000 1.85 5332 0
1999 1.76 5079 1d
1998 1.72 5009 0
AFP, acute ﬂaccid paralysis.
a See references 6 and 7.
b Immunodeﬁciency vaccine-derived polio cases (iVDPV).
c Three VDPV cases.
d Polio case due to infection with imported wild polio virus.This had an immediate effect on the two rounds of the national
campaign (winter and spring) from 1994 to 1995. The Luxembourg
government donated US$ 2 million worth of vaccine cold storage
systems to the epidemic prevention departments in counties and
towns that were short of, or urgently demanding, new cold chain
equipment in the campaign to eradicate polio.2
The West Paciﬁc Certiﬁcation Commission on Poliomyelitis
Eradication ofﬁcially signed in October 2000, conﬁrmed that China
and the West Paciﬁc region it belongs to were polio-free. No
indigenous and overseaWPV case has been reported in China since
2000. However, polio cases have been reported in China’s
neighbors, including India, Pakistan, and Afghanistan. In addition,
the low poliomyelitis live oral vaccine inoculation rate in polio-free
countries like Indonesia has caused the outbreak of importedWPV
in this area.
Aside from its critical role in boosting immunity, for the ﬁrst
time in 1996, the Chinese government also applied the industrial
‘Batch Quality Sampling InspectionMethod’ to survey and appraise
the inoculation rate and effectively solved the appraisal of the
small-sample inoculation rate in towns. Researchers adopted
the virology classiﬁcation criteria for AFP in 1997 to make the
monitoring results more accurate and complete. The State Polio
Laboratory established the gene pool of the local wild virus
sequence through sequence analysis and the ELISA method for the
inspection of polio IgM and IgG antibodies during the ‘9th ﬁve-year’
period.
China was also the ﬁrst country to discover and report the
existence of the recombinant virus of wild virus and vaccine virus
and the natural recombinant virus from the different types of
vaccines, and their signiﬁcance to epidemiology.10classiﬁed result
ld virus polio cases Polio compatible cases Diseased cases
1 3000b
10 5625b
16 5409b
19 5266c
21 5086
20 5395
19 5376
17 5315
33 5045
44 4965
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polio-free target, the Chinese government continuously improved
themethods and quality of the Immunity Boost national campaign.
When it was especially close to certiﬁcation, China adjusted the
strategy and introduced the ‘Sub-National Immunity Boost’
campaign, developed 10 rounds (ﬁve times) of immunity boost,
inoculated children a total of 500 million person-times, and
guaranteed the health of children in this populous country.
To avoid the recurrence of polio, uptake of the oral polio vaccine
became a statutory obligation after two month yeas old in China
1993. However, the oral pill triggers abnormal reactions and even
causes serious consequences, such as disability. Hence, this
aroused social conﬂicts, which became serious as more children
were affected. This raised new issues for the Chinese government
to consider. In the second half of 2005, parents from different
provinces took their children with abnormal limbs to seek medical
treatment in Beijing. Theywere surprised to ﬁnd that their children
had all taken the poliomyelitis live oral vaccine after birth. Despite
this, the incidence rate of vaccine-associated paralytic poliomyeli-
tis (VAPP) was quite low. The total incidence rate of VAPP cases in
Beijing from1989 to 2002was 1.2/million and that of contact VAPP
cases was 0.16/million.11 VAPP cases in Chinawere estimated to be
between 0.27 and 2.82/million in 2007 .12
Since the immunity plan beneﬁts the majority of children, the
state should improve laws and statutes and reasonably compen-
sate the unavoidable ‘one-in-a-million’ victims. However, China
did not have such a policy or laws for reference. From July 2006 to
July 2008, TheMinistry of Health of the People’s Republic of China
held demonstration and coordination meetings involving many
experts from the relevant departments. The Ministry persisted
with the national inoculation policy, but also analyzed how to
recognize and avoid VAPP in China. In coordination with several
government departments, the Ministry likewise issued the
‘Instruction advice on veriﬁcation of cases related to polio
vaccines and handling of remaining problems’ (Wei Ban Fa
[2008] No. 40) on July 17, 2008 and proposed solutions for the
VAPP issues. The Chinese government established suitable
insurance and guarantee mechanisms, and truly guaranteed the
rights of each VAPP patient.
4. Poliomyelitis vaccine
The continuous use of the poliomyelitis live oral vaccine is
contradictory to the eradication of polio. The poliomyelitis live
oral vaccine can trigger polio, as the poliovirusmay originate from
the poliomyelitis live oral vaccine. This may then be transmitted
extensively, resulting in the failure of the eradication plan. To
ensure the permanent eradication of polio, the regular use of the
poliomyelitis live oral vaccine must be stopped; this needs
political support and resource guarantees. Only thenwillmankind
stop being paralyzed as a result of poliovirus infection. The
continuous use of the poliomyelitis live oral vaccine after
intercepting the transmission of WPV could cause polio through:
(1) VAPP,12 (2) an outbreak due to vaccine-derived poliovirus
circulation,13–15 and (3) the excreta of the population with
primary immunodeﬁciency containing vaccine-derived poliovi-
rus, for years to come.
The advantage of the inactivated poliovirus vaccine (IPV) is that
it is safe; however the period of immunity retention is short and
hence it has to be injected repeatedly. Moreover, the intestinal
tract cannot acquire local immunological competence.
China is surrounded by four countries that are still polio-
endemic. Aside from expense concerns, the Chinese government is
worried that the current high-coverage of antibody cannot be
maintained if the poliomyelitis live oral vaccine is stopped, and as a
result the disease will recur.5. Conclusions
After two decades of ﬁghting against polio, the Chinese
government still faces an arduous task as a result of the need to
(1) prevent the entry and transmission of WPV from the polio-
endemic surrounding countries, (2) detect and stop outbreaks of
polio caused by the recycling vaccine-derived poliovirus, (3)
reduce VAPP cases, and (4) improve the State compensation
system.
To achieve these targets, the Chinese government should
continue with and/or improve the following: ﬁrst of all high-level
coverage of regular immunization should be maintained and high-
level immunization should be strengthened and maintained in
order to stop the transmission of poliomyelitis among the people.
Regular immunization is the foundation of poliomyelitis eradica-
tion. Immunization should consist of two elements: (1) enhanced
and emergency immunization: the enhanced immunization of
poliomyelitis vaccine aims to reinforce the immunological barrier
and reduce zero-dose children for immunization and (2) a
reduction in the incidence of VAPP; the IPV was launched in the
USA for the regular immunization of children in 2000.
Secondly, a sensitive and efﬁcient surveillance system should
be established, with: (1) the poliomyelitis laboratory network as
the foundation for surveillance of AFP cases. The surveillance
results will help us to identify the more dangerous regions and
populations, improving the diagnosis of cases and strengthening
immunological prevention and scientiﬁc management; this will
help to stop the possible transmission of wild-type poliovirus; (2)
surveillance of epidemic situations: poliomyelitis is an interna-
tional epidemic disease and we must always be alert. We should
strengthen quarantine control in border areas, preventing its
import from the outside; identify, report, and diagnose patients in
time; predict and forecast the epidemic situation of poliomyelitis;
and give instructions on preventive measures; (3) the ability to
identify in a timelymanner and respond to the import of wild-type
poliovirus and the circulation of vaccine-derived poliovirus
(VDPV). China should be able to adopt powerful measures once
the epidemic situation is identiﬁed, control the outbreak, eradicate
the danger of circulation of the wild virus, stop its possible
transmission, and wipe out the epidemic situation to reinforce its
position as a non-polio state, until its eradication in the global
context.
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